FDA approved “Fedratinib” (Inrebic) capsules for rare adult patients with special forms of Myelofibrosis.
The chronic rare condition with scar tissue formation on the bone marrow and enlargement of organs are known as “Myelofibrosis” which had previously the approval therapy in Ruxolitinib (Jakati) and after 8 years, “Fedratinib” from impact biomedicines has been approved and indicated for the treatment of such rare condition. The approval is based on the results of a clinical trial comparing 2 different therapy doses (400 mg or 500 mg per day) in 289 adult patients.
A total of 36 patients treated with “Fedratinib” reported a reduction of more than %50 in Myelofibrosis-related symptoms including night sweats , itching, abdominal discomfort, pain under ribs on their left side and pain in the bones and muscles, among others.
Source : HCP Live Network